BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 23338487)

  • 1. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
    Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
    Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
    Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
    Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
    Roila F; Ruggeri B; Ballatori E; Fatigoni S; Caserta C; Licitra L; Mirabile A; Ionta MT; Massidda B; Cavanna L; Palladino MA; Tocci A; Fava S; Colantonio I; Angelelli L; Ciuffreda L; Fasola G; Zerilli F
    Ann Oncol; 2015 Jun; 26(6):1248-1253. PubMed ID: 25743855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
    Hamada S; Hinotsu S; Kawai K; Yamada S; Narita S; Kamba T; Nishiyama H; Arai Y; Habuchi T; Ogawa O; Kawakami K
    Support Care Cancer; 2014 Aug; 22(8):2161-6. PubMed ID: 24652048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002).
    Ishido K; Higuchi K; Azuma M; Sasaki T; Tanabe S; Katada C; Yano T; Wada T; Koizumi W;
    Anticancer Drugs; 2016 Oct; 27(9):884-90. PubMed ID: 27254283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
    Shi Q; Li W; Li H; Le Q; Liu S; Zong S; Zheng L; Hou F
    Oncotarget; 2016 Apr; 7(17):24402-14. PubMed ID: 27015550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.
    Takeshima N; Matoda M; Abe M; Hirashima Y; Kai K; Nasu K; Takano M; Furuya K; Sato S; Itamochi H; Tsubamoto H; Hasegawa K; Terao K; Otsuki T; Kuritani K; Ito K
    Support Care Cancer; 2014 Nov; 22(11):2891-8. PubMed ID: 24825735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
    Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
    Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial.
    Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Kimura M; Taguchi T; Yoshida T; Nagao J; Sakuma Y; Toth G
    Int J Clin Oncol; 2009 Aug; 14(4):337-43. PubMed ID: 19705245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
    Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
    Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.
    Choi CH; Kim MK; Park JY; Yoon A; Kim HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS
    Support Care Cancer; 2014 May; 22(5):1181-7. PubMed ID: 24337621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
    Martin AR; Carides AD; Pearson JD; Horgan K; Elmer M; Schmidt C; Cai B; Chawla SP; Grunberg SM
    Eur J Cancer; 2003 Jul; 39(10):1395-401. PubMed ID: 12826042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.